|
New Quality Office Needed to Link Preapprovals, GMPs: FDA Officials
BALTIMORE — CDER is exploring the creation of a new Office of Pharmaceutical Quality (OPQ) that would oversee quality throughout a drug’s lifecycle — partially by promoting GMP standards in the preapproval setting, FDA officials say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives